🇺🇸 Tegafur-uracil (UFT) in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bone Marrow Failure — 1 report (10%)
  2. Dehydration — 1 report (10%)
  3. Depressed Level Of Consciousness — 1 report (10%)
  4. Disease Progression — 1 report (10%)
  5. Erythema — 1 report (10%)
  6. Extravasation — 1 report (10%)
  7. General Physical Health Deterioration — 1 report (10%)
  8. Hypersensitivity — 1 report (10%)
  9. Pruritus — 1 report (10%)
  10. Rash — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Tegafur-uracil (UFT) approved in United States?

Tegafur-uracil (UFT) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tegafur-uracil (UFT) in United States?

Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.